¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"surface envelope model"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • proportional hazards model
    ºñ·ÊÀ§Çè¸ðÇü
  • psychodynamic experiential model
    Á¤½Å¿ªµ¿°æÇè¸ðÇü
  • reserve model
    ¿¹ºñ¸ðÇü
  • role model
    ¿ªÇÒÇ¥º»Çü, ¿ªÇÒ¸ðµ¨
  • social service model
    »çȸ¼­ºñ½º¸ðµ¨
  • statistical model
    Åë°è¸ðÇü
  • symmetry model
    ´ëĪÇü, ´ëμ³
  • sequential model
    ¼øÂ÷¸ðµ¨
  • single major gene locus model
    ´ÜÀÏÁÖ¿äÀ¯ÀüÀÚÀÚ¸®¸ðÇü
  • viscoelastic model
    Á¡µµÅº·Â¸ðÇü
  • working model
    ÀÛ¾÷¸ðÇü
  • wax model
    ¹Ð¶ø¸ðÇü
  • approximal surface
    Á¢Ã˸é, ÀÎÁ¢¸é
  • articular surface
    °üÀý¸é
  • body surface mapping
    üǥ¸éÀüÀ§Áöµµ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • plaster model
    ¼®°í¸ðÇü
  • proportional hazards model
    ºñ·ÊÀ§Çè¸ðÇü
  • psychodynamic experiential model
    Á¤½Å¿ªµ¿°æÇè¸ðÇü
  • reserve model
    ¿¹ºñ¸ðÇü
  • role model
    ¿ªÇÒÇ¥º»Çü
  • sequential model
    ¼øÂ÷¸ðµ¨
  • single major gene locus model
    ´ÜÀÏÁÖ¿äÀ¯ÀüÀÚÀÚ¸®¸ðÇü
  • social service model
    m. »çȸ¼­ºñ½º¸ðµ¨
  • statistical model
    Åë°è¸ðÇü
  • symmetry model
    ´ëĪÇü, ´ëμ³
  • time dependent relative risk model
    ½Ã°£ÀÇÁ¸»ó´ëÀ§Çè¸ðµ¨
  • viscoelastic model
    Á¡µµÅº·Â¸ðÇü
  • wax model
    ¹Ð¶ø¸ðÇü
  • working model
    ÀÛ¾÷¸ðÇü
  • anterolateral surface
    ¾Õ°¡Âʸé
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • gluteal surface
    µÐºÎ±Ù¸é, µÐ±Ù¸é(ÔëÐÉØü).
  • gluteal surface
    º¼±â±Ù¸é
  • gluteal surface
    µÐ ¸é, µÐºÎ±Ù ¸é, µÐ±Ù ¸é(ÔëÐÉØü).
  • hepatitis B surface antigen (HBs Ag)
    BÇü °£¿°¹ÙÀÌ·¯½º Ç¥¸éÇ׿ø
  • hepatitis B surface antigen(HBs Ag)
    BÇü °£¿°Ç¥¸éÇ׿ø
  • immunoglobulin, surface
    ¼¼Æ÷Ç¥¸é ¸é¿ª±Û·ÎºÒ¸°
  • impression of root surface
    ±Ù¸éÀλó(ÐÆØü ìÔßÚ).
  • incisal surface
    Àý´Ü¸é(ôîÓ®Øü).
  • inferior articular surface
    ¾Æ·¡°üÀý¸é
  • inferior surface
    ¾Æ·¡¸é
  • inferior surface of petrous portion
    ¹ÙÀ§¾Æ·¡¸é
  • inferior surface of tongue
    Çô¾Æ·¡¸é
  • plantar surface of toes
    ¹ß°¡¶ô¹Ù´Ú
  • popliteal surface
    ¿À±Ý¸é
  • posterior articular surface
    µÚ°üÀý¸é
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • multitarget single hit model
    ´ÙÇ¥Àû´ÜÀÏÀûÁß
  • nuclear model
    (¿øÀÚ)ÇÙ¸ðÇü(ê«í­ú·Ù¼úþ).
  • organic model
    À¯±â¸ðÇü(¡­Ù¼úþ).
  • plaster model
    ±é½º Çü(¡­úþ), ¼®°í ¸ðÇü.
  • psychodynamic experiential model
    Á¤½Å¿ªµ¿Àû °æÇè¸ðµ¨
  • reserve model
    ¿¹ºñ¸ðÇü(çãÝáÙ¼úþ).
  • role model
    ¿ªÇÒÇ¥º»Çü(Ëç̰̰ËÓÌ´).
  • sequential model
    ¼øÂ÷¸ðµ¨.
  • single major gene(locus) model
    ´ÜÀÏ ÁÖ¿äÀ¯ÀüÀÚ(À¯ÀüÁÂÀ§) ¸ðµ¨
  • single target multi-hit model
    ´ÜÀÏÇ¥Àû´Ù¹ßÀûÁß ¸ðµ¨
  • social service model
    »çȸ¼­ºñ½º¸ðµ¨
  • stress and coping model
    ½ºÆ®·¹½º¿Í ´ëó(Óßô¥)¸ðµ¨.
  • symmetry model
    ´ëĪÇü(Óßöàúþ), ´ëμ³(Óß öàæò).
  • time dependent relative risk model
    ½Ã°£ÀÇÁ¸¼º »ó´ëÀ§Çè¸ðµ¨
  • viscoelastic model
    Á¡Åº¼º¸ðÇü.
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Dorsal surface
    µîÂʸé
    [¿¾ ¿ë¾î] ¹èÃø¸é
  • Distal surface
    ¸ÕÂʸé
    [¿¾ ¿ë¾î] ¿ø½É¸é
  • Arytenoid articular surface
    ¸ð»Ô°üÀý¸é
    [¿¾ ¿ë¾î] ÇÇ¿­°üÀý¸é
  • Intervertebral surface
    ¸öÅë»çÀ̸é
    [¿¾ ¿ë¾î] Ãß°£¸é
  • Patellar surface
    ¹«¸­¸é
    [¿¾ ¿ë¾î] ½½°³¸é
  • External surface
    ¹Ù±ù¸é
    [¿¾ ¿ë¾î] ¿Ü¸é
  • Posterior surface of petrous portion
    ¹ÙÀ§µÚ¸é
    [¿¾ ¿ë¾î] ÃßüÈĸé
  • Inferior surface of petrous portion
    ¹ÙÀ§¾Æ·¡¸é
    [¿¾ ¿ë¾î] ÃßüÇϸé
  • Anterior surface of petrous portion
    ¹ÙÀ§¾Õ¸é
    [¿¾ ¿ë¾î] ÃßüÀü¸é
  • Lunate surface
    ¹Ý´Þ¸é
    [¿¾ ¿ë¾î] ¿ù»ó¸é
  • Dorsal surface of toes
    ¹ß°¡¶ôµî
    [¿¾ ¿ë¾î] Á·Áö¹è¸é
  • Plantar surface of toes
    ¹ß°¡¶ô¹Ù´Ú
    [¿¾ ¿ë¾î] Á·Áöô¸é
  • Articular surface for navicular bone
    ¹ß¹è°üÀý¸é
    [¿¾ ¿ë¾î] ÁÖ»ó°ñ°üÀý¸é
  • Thyroid articular surface
    ¹æÆÐ°üÀý¸é
    [¿¾ ¿ë¾î] °©»ó°üÀý¸é
  • Ventral surface
    ¹èÂʸé
    [¿¾ ¿ë¾î] º¹Ãø¸é
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • CPK model
    CPK ¸ðµ¨
  • crystallographic model
    °áÁ¤(Ì¿ïÜ) ¸ðµ¨
  • Danielli-Davson model
    ´Ù´Ï¿¤¸®-´ëºê¼Õ ¸ðµ¨
  • Danielli-Davson-Robertson model
    "= unit membrane hypothesis, ´Ù´Ï¿¤¸®-´ëºê¼Õ-·Î¹öÆ®¼Õ ¸ðµ¨"
  • distorted bond model
    ¿Ö°î°áÇÕ(èàÍØÌ¿ùê) ¸ðµ¨
  • doughnut model
    µµ¿ì³Ó ¸ðµ¨
  • Dreiding model
    µå¶óÀ̵ù ¸ðµ¨
  • erosion model
    ¹Ì¶õ(Ú¼Õ´) ¸ðµ¨
  • Ferdinand model
    Æä¸£µð³­µå ¸ðµ¨
  • floating receptor model
    ºÎÀ¯ ¼ö¿ëü(Ý©ë´áôé»ô÷) ¸ðµ¨
  • fluid mosaic model
    À¯µ¿(×µÔÑ) ¸ðÀÚ
  • framework model
    °ñ°Ý(ÍéÌ«) ¸ðµ¨
  • Holliday model
    ÇÒ·¯µ¥ÀÌ ¸ðµ¨
  • Huxley-Hanson model
    Çä½½¸®-Çî½¼ ¸ðµ¨
  • Huxley-Simmons model
    Çä½½¸®-½Ã¸ó½º ¸ðµ¨
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
ICM inner cell mass; integrated conditional model; intercostal margin; International Confederation of Mi...
MAU multi-attribute utility [model]
MIC maternal and infant care; medical intensive care; Medical Interfraternity Conference; microscopy; mi...
OSI open systems interconnection [reference model]
PBPK physiologically based pharmacokinetic [model]
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
POHEM POpulation HEalth Model
TTM The Transtheoretical Model
UKM Urea kinetic model
MAIDS model of AIDS
CE cell envelope
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • boundary surface
    °è¸é
    µ¿ÀǾî=interface.
  • cardiac surface map
    ½ÉÀå Ç¥¸éµµ
  • cell surface marker
    ¼¼Æ÷ Ç¥¸é Ç¥ÁöÀÚ
  • contact surface
    Á¢Ã˸é
    °£È¤ »óÇÏ Ä¡¾Æ°£ ±³ÇÕ¸é Á¢ÃËÀ» °¡¸®Å°´Â °æ¿ìµµ ÀÖ´Ù.
  • costal surface
    ´Á°ñ ¸é
  • disc-articular surface adherence
    °üÀý¿øÆÇ-°üÀý ¸é À¯Âø
  • dorsal surface of finger
    ¼Õ°¡¶ô µî
  • equipotential surface
    µîÀüÀ§ ¸é
  • exposed surface
    ³ëÃâ¸é
  • fatty coating of surface
    Ç¥¸éÀÌ Áö¹æÀ¸·Î µ¤Çô ÀÖ´Â
  • flexor surface
    ±¼°î¸é, ±¼±Ù¸é
  • free surface
    ÀÚÀ¯ ¸é
  • high surface
    °íÇ¥¸é
  • impression of root surface
    ±Ù¸é Àλó
  • impression surface
    Àλó¸é
    ±¸°­ Á¶Á÷ÀÇ ÀÎ»ó¿¡ ÀÇÇØ¼­ °áÁ¤µÈ ÀÇÄ¡ÀÇ Ç¥¸é.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
concerted model A model used to explain the allosteric form of cooperativity; in this model, an oligomeric protein can exist in two conformational states in the absence of the ligand; these states are in equilibrium and the one that is predominant has a lower affinity for the ligand (which binds to the protein in a rapid equilibrium fashion).
Synonym: concerted model.
(05 Mar 2000)
multiplicative model A model in which the joint effect of two or more causes is the product of their effects if they were acting alone.
(05 Mar 2000)
multistage model A mathematical model, mainly for carcinogenesis, based on the theory that a specific carcinogen may affect one among a number of stages in the development of cancer.
(05 Mar 2000)
continuous time model <epidemiology> A model in which the system changes continuously over time. Derivatives (e.g. DY/dt ) are the mathematical formalism for describing such continuous change. The differential equation which embodies a model provides the values of these derivatives at any particular time point; calculus or a computer can then be used to move the state of the model forwards in time.
Continuous models have the advantage over discrete time models in that they are more amenable to algebraic manipulation, although they are slightly harder to implement on a computer.
The same as a differential equation model.
(05 Dec 1998)
cooperativity model A model used to explain the property of cooperativity observed in certain enzymes; e.g., allosterism or hysteresis.
(05 Mar 2000)
seir model <epidemiology> A class of compartmental prevalence models, with compartments Susceptible, Latent (Exposed), Infectious and Recovered. Takes its name from a common notation. In the notation used in the course, this would be an XHYZ model. Many permutations possible.
(05 Dec 1998)
sliding filament model <cell biology> Generally accepted model for the way in which contraction occurs in the sarcomere of striated muscle, by the sliding of the thick filaments relative to the thin filaments.
(18 Nov 1997)
spawner-recruit model Biological model that relates the number of recruits or mature spawners in one generation to the number of spawners in the previous generation.
(09 Oct 1997)
statistical model A formal representation for a class of processes that allows a means of analyzing results from experimental studies, such as the Poisson model or the general linear model; it need not propose a process literally interpretable in the context of the individual case.
(05 Mar 2000)
stochastic model <epidemiology> A mathematical model which takes into consideration the presence of some randomness in one or more of its parameters or variables. The predictions of the model therefore do not give a single point estimate but a probability distribution of possible estimates. Contrast with deterministic.
We might distinguish demographic stochasticity which arises from the discreteness of individuals and individual events such as birth, and environmental stochasticity arising from more-or-less unpredictable interactions with the outside world.
(05 Dec 1998)
nursing model A set of abstract and general statements about the concepts that serve to provide a framework for organizing ideas about clients, their environment, health and nursing.
(05 Mar 2000)
deterministic model <epidemiology> A mathematical model in which the parameters and variables are not subject to random fluctuations, so that the system is at any time entirely defined by the initial conditions chosen. Contrast with a stochastic model.
(05 Dec 1998)
discrete time model <epidemiology> A model in which the system jumps from one state to the next at fixed intervals or timesteps. These difference models are simple to understand but often difficult to analyse; Contrast continuous time models.
The parameters in such a model refer to the amount of change over the finite timestep; they are sometimes referred to as finite rates.
In a (rather precise) sense, a differential equation is what you eventually get from a difference equation when you let the timestep get smaller and smaller and smaller.
(05 Dec 1998)
induced fit model A model to suggest a mode of action of enzymes in which the substrate binds to the active site of the protein, causing a conformational change in the protein.
Synonym: Koshland-Nemethy-Filmer model.
(05 Mar 2000)
transition probability model A model to account for the apparently random variation in cell cycle time between individual animal tissue cells in culture that postulates that transition from G1 to s phase is probabilistic. Contrasts with hypotheses that require the accumulation of critical levels of particular proteins.
(18 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á